Page last updated: 2024-09-03
ym 022 and tetragastrin
ym 022 has been researched along with tetragastrin in 1 studies
Compound Research Comparison
| Studies (ym 022) | Trials (ym 022) | Recent Studies (post-2010) (ym 022) | Studies (tetragastrin) | Trials (tetragastrin) | Recent Studies (post-2010) (tetragastrin) |
|---|---|---|---|---|---|
| 65 | 1 | 8 | 544 | 72 | 32 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brammer, N; Dunlop, J; Ennis, C; Evans, N | 1 |
Other Studies
1 other study(ies) available for ym 022 and tetragastrin
| Article | Year |
|---|---|
YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea]: an irreversible cholecystokinin type-B receptor antagonist.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Humans; Phenylurea Compounds; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Signal Transduction; Tetragastrin; Transfection | 1997 |